Navigation Links
Research: Dosage of Morphine for ill Newborns Still too Imprecise

LEIDEN, The Netherlands, December 22 /PRNewswire/ -- Dosage recommendations for newborns being cared for in an intensive care unit will in the future most likely be based on more individual characteristics than just body weight. This is the result of a study conducted by the Dutch Top Institute Pharma in which Leiden University (Prof M. Danhof) and the Rotterdam Erasmus Medical Centre/Sophia Children's Hospital (Prof D. Tibboel) are represented.

Catherijne Knibbe, clinical pharmacologist from the Leiden/Amsterdam Centre for Drug Research of Leiden University: "For morphine the preliminary study results show that for example a quarter of the current standard dose is sufficient for premature babies. The Erasmus MC/Sophia Children's Hospital had already noted in practice that some babies experienced withdrawal symptoms after long-term treatment with morphine. Now research has shown that the required amount of morphine can vary greatly per baby."

The dosage for children is often adjusted solely according to body weight, but that now seems to be insufficient. Knibbe said about the common used sedative midazolam: "A healthy child may be prescribed far more midazolam than for example a child with the same body weight lying in the intensive care unit with a severe infection. This study provides guidelines for arriving at a dosage recommendation that is adjusted better to the individual child. This is an enormous advance." According to Knibbe, this information is very important for doctors, as well as for pharmaceutical companies, which have been required for the past two years to conform to stricter European legislation for medicinal products for children.

This study required an intensive collaboration between clinical pharmacologists and pediatricians from the various institutes using modern methods like PK/PD modeling. Complex computer models can determine the correct dosage from small quantities of blood, taking into account the child's specific characteristics. Knibbe: "We know too little about the effects of medicinal products on children, especially newborns. Although we actually need more information than for adults. Children change so rapidly. In the first year of life the child changes each week, and responds differently and breaks down medicinal products differently. I think that these study results will mean that in some cases children will receive less medication, and thus fewer adverse effects will develop, while the child will still be treated well. I consider that a major benefit: for doctors, but most especially for the children and their parents."

The Top Institute Pharma is a collaboration between universities, university medical centers and pharmaceutical companies. This intensive collaboration accelerates research into new medicinal products and a better use of medication. The Dutch Ministry of Public Health, Welfare and Sport supports the Top Institute Pharma.

For more information, please contact Albert Reinders: +31-6-53184737.

SOURCE Top Institute Pharma

SOURCE Top Institute Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ
2. Important Step Forward in Osteoarthritis Research: Bioactive Collagen Peptides Stimulate the Regeneration of Cartilage Tissue
3. Setting the Benchmark for Winery Tasting Room Research: An Emerging Region Gets a Global Perspective
4. New Weapon in BioDefense Research: NanoLogix Kit Speeds Rapid Diagnostics of Anthrax and Bubonic Plague
5. Encouraging high-risk research: DFG approves funding for 2 new Reinhart Koselleck projects
6. U-M research: New plastic is strong as steel, transparent
7. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
8. Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding
9. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
10. ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets
11. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
Post Your Comments:
(Date:11/24/2015)... 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ... New York on Wednesday, December 2 at 9:30 ... president and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim ... provide a corporate overview. --> th Annual Oppenheimer ...
(Date:11/24/2015)... ... 2015 , ... International Society for Pharmaceutical Engineering (ISPE) closed ... events for pharmaceutical manufacturing: 2015 Annual Meeting. The conference took place in Philadelphia, ... number of attendees in more than a decade. , “The 2015 Annual ...
(Date:11/24/2015)... PUNE, India , November 24, 2015 ... to a new market research report "Oligonucleotide Synthesis Market ... Equipment), Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User ... to 2020", published by MarketsandMarkets, the market is expected ... 1,078.1 Million in 2015, at a CAGR of 10.1% ...
(Date:11/24/2015)... , November 24, 2015 SHPG ) announced ... in the Piper Jaffray 27 th Annual Healthcare Conference in ... 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). --> ... Financial Officer, will participate in the Piper Jaffray 27 th ... NY on Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 ...
Breaking Biology Technology:
(Date:10/29/2015)... Daon, a global leader in mobile biometric ... new version of its IdentityX Platform , IdentityX ... have already installed IdentityX v4.0 and are ... FIDO UAF certified server component as an option ... features. These customers include some of the largest and ...
(Date:10/29/2015)... -- Connected health pioneer, Joseph C. Kvedar , MD, ... and wellness, and the business opportunities that arise from ... of Healthy Things . Long before health and ... Kvedar, vice president, Connected Health, Partners HealthCare, was creating ... from the hospital or doctor,s office into the day-to-day ...
(Date:10/29/2015)... Oct. 29, 2015 Today, LifeBEAM ... partnership with 2XU, a global leader in technical ... smart hat with advanced bio-sensing technology. The hat ... to monitor key biometrics to improve overall training ... the two companies will bring together the most advanced ...
Breaking Biology News(10 mins):